Share on LinkedInShare on LinkedIn

ARTICLE · 30 MAY 2018

FDA Final Guidance On: Bioanalytical Method Validation

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

On May 21, 2018, FDA issued final guidance on Bioanalytical Method Validation. The guidance incorporates public comments to the revised draft published in 2013 ...

United StatesFood, Drugs, Healthcare, Life Sciences

On May 21, 2018, FDA issued final guidance on Bioanalytical Method Validation.  The guidance incorporates public comments to the revised draft published in 2013, which followed an initial release of guidance in 2001, and reflects advances in science and technology.  The guidance describes the elements of bioanalytical method development and validation that are needed to ensure the quality of an assay and the reliability of the data it generates. 

The guidance is meant to help when validating bioanalytical methods used in human clinical pharmacology, bioavailability, and bioequivalence studies and applies to bioanalytical procedures such as chromatographic assays and ligand binding assays that quantitatively determine the levels of drugs, their metabolites, therapeutic proteins, and biomarkers in biological matrices such as blood, serum, plasma, urine, and tissue such as skin.  The guidance may also inform the development of bioanalytical methods used for certain

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from